A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.

M, Yellin; I, Paliienko; A, Balanescu; S, Ter-Vartanian; V, Tseluyko; LA, Xu; X, Tao; PM, Cardarelli; H, Leblanc; G, Nichol; C, Ancuta; R, Chirieac; A, Luo

doi:10.1002/art.34330

Public

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis.

Shared by NobleBlocks on Dec 6, 2011 • 12:00 AM UTC

Authors:

Yellin M

Paliienko I

Balanescu A

Abstract

Objective CXCL10 (also known as interferon-γ-inducible 10-kd protein [IP-10]) is a chemokine that potentially plays a role in the immunopathogenesis of rheumatoid arthritis (RA). We undertook this phase II study to evaluate the efficacy and safety of MDX-1100, a fully human, anti-CXCL10 (anti-IP-10)...

Discussions